GlucoTrack, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $4.2 million, a decrease from a loss of $5.1 million in the same period last year. For the nine-month period ending September 30, 2025, the company recorded a net loss of $15.8 million, compared to a loss of $12.5 million for the same period in 2024. The increase in losses is attributed to higher general and administrative expenses, which rose to $4.0 million from $2.6 million year-over-year, primarily due to increased legal and professional fees.
Total operating expenses for the nine-month period were approximately $12.6 million, up from $10.7 million in the previous year. Research and development expenses also increased, totaling $8.2 million compared to $7.8 million in 2024, reflecting ongoing efforts in product development for the implantable continuous blood glucose monitor (CBGM). The company’s cash and cash equivalents stood at $7.9 million as of September 30, 2025, an increase from $5.6 million at the end of 2024, largely due to financing activities that generated $13.5 million in net proceeds.
In terms of strategic developments, GlucoTrack has made significant progress in its clinical studies for the CBGM, which aims to provide continuous glucose monitoring without the lag time associated with traditional methods. The company completed a first-in-human clinical study in early 2025, achieving all primary and secondary endpoints with no serious adverse events reported. Following this, a long-term clinical study has been initiated to further evaluate the product's performance and safety. The company is also preparing for a pre-investigational device exemption submission to the FDA, expected in Spring 2026.
Operationally, GlucoTrack has seen an increase in its stockholder equity, which rose to $2.8 million from a deficit of $13.0 million at the end of 2024. The company has also undergone significant changes in its capital structure, including a reverse stock split and an increase in authorized shares from 100 million to 250 million. As of September 30, 2025, the company had 899,410 shares outstanding, reflecting its recent equity financing efforts.
Looking ahead, GlucoTrack anticipates that it will require approximately $15 million in cash to fund its operations over the next twelve months. The company acknowledges substantial doubt regarding its ability to continue as a going concern without securing additional financing. Management is actively exploring various funding options, including equity and debt financing, to support its ongoing clinical trials and operational needs.
About GlucoTrack, Inc.
Glucotrack, Inc. develops innovative medical devices focused on non-invasive and implantable continuous blood glucose monitoring systems for people with Type 1 and insulin-dependent Type 2 diabetes. Its core product, the Glucotrack CBGM, aims to provide long-term, accurate, and convenient glucose measurement without fingersticks. The company targets the growing diabetes market, leveraging advanced sensor technology, regulatory expertise, and strategic manufacturing partnerships to improve patient outcomes and address unmet needs in glucose management.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.